Titan Pharmaceuticals Inc. said the European Medicines Agency accepted the company's marketing authorization application for Probuphine for review.
Probuphine is a substitution treatment for opioid drug dependence.
The drug is available in the U.S. as the only six-month treatment for opioid dependence that delivers buprenorphine continuously.
